Axio BioPharma

AI-driven CDMO for small-scale monoclonal antibody manufacturing


Name	Axio BioPharma
Tagline	Data infrastructure for biomanufacturing process coordination
Headquarters	Madison, WI, United States
Founded	2024
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America, Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Seed

The Short Version

Axio BioPharma is a biomanufacturing data infrastructure company that provides a vendor-neutral coordination layer for process data. The company, founded in Madison, Wisconsin in August 2024, operates two product lines: Axio Forge, a high-throughput antibody production facility, and Axio Lattice, a federated data infrastructure. Axio aims to solve the problem of disparate enterprise systems in biomanufacturing that hinder tech transfer and data-driven decision-making.

The founding team includes CEO Justin Byers, who held commercial leadership roles at Illumina, Aldevron, Cambrex, and Fujifilm Diosynth Biotechnologies, and Co-founder and CTO Brian Staats, an early engineer at CrowdStrike with a background in bioinformatics and distributed systems. The company has raised approximately $1.3 million to date and is actively raising a $6 million seed round. Axio is engaged with seven of the top 10 global pharma companies and has collaboration partnerships with Shimadzu and Likarda. The company has also registered Axio BioPharma Ireland Limited in Dublin, Ireland.

Data Accuracy: GREEN -- Core service description, team, funding, and commercial traction are confirmed by company sources and public profiles.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America, Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

The Company in Brief

Axio BioPharma was launched in August 2024 to address the challenges of data coordination in biomanufacturing. The company's operations are based in Madison, Wisconsin, at the Forward BioLabs incubator. Axio operates two distinct but complementary product lines: Axio Forge and Axio Lattice.

Axio Forge is a US-based, non-GMP, high-throughput antibody production facility located at Forward BioLabs. This facility builds commercial relationships and domain credibility that convert into deployments of Axio Lattice. Axio Lattice is a federated, vendor-neutral data infrastructure that normalizes and connects process data across pharma sponsors and manufacturing partners. This system allows data to remain within the sponsor's environment, ensuring data ownership never changes hands and eliminating the need for data lakes or third-party aggregation.

Key early milestones include moving into the Forward BioLabs facility and hiring its first scientific staff members by November 2024. In 2025, the company began expanding its advisory board, adding Dr. Greg Bleck, Dr. Graham Brearley, and Patrick Haffey. A collaboration partnership with Shimadzu is underway. Axio has also registered Axio BioPharma Ireland Limited in Dublin, Ireland.

Data Accuracy: GREEN -- Key dates, location, product lines, and partnerships are corroborated by company sources and public records.

What They Have Built

The company's core offering is a data infrastructure solution for biomanufacturing, designed to address the fragmentation of process data across various enterprise systems. Axio BioPharma operates two product lines: Axio Forge and Axio Lattice.

Axio Forge is a US-based, non-GMP, high-throughput antibody production facility. This facility is instrumental in building commercial relationships and establishing domain credibility, which in turn facilitates the deployment of Axio Lattice. Axio Lattice is a federated, vendor-neutral data infrastructure that functions as a coordination layer. It normalizes and connects process data from diverse sources, such as Historian, MES, LIMS, ELN, ERP, and QMS systems. This approach ensures that data never leaves the sponsor's environment and ownership remains with the sponsor, eliminating the need for data lakes, third-party aggregation, or complex data sharing agreements.

Axio is actively engaged in CDA and scoping conversations with multiple top-10 pharma sponsors and global manufacturing partners. A joint experiment scope and co-authored white paper are in progress with Likarda.

Data Accuracy: GREEN -- Core service description, product lines, and technology claims are confirmed by company sources and ongoing commercial engagements.

Market Size and Demand

Axio BioPharma operates in the biomanufacturing data infrastructure market. The broader biopharmaceutical industry's R&D spending continues to rise, with a significant portion directed toward biologic candidates, including monoclonal antibodies, cell therapies, and gene therapies [IQVIA Institute, 2024]. This creates a structural need for flexible, external manufacturing capacity and improved data management.

The market for bioprocess data platforms is emerging, with solutions focused on integrating and analyzing data from various stages of biomanufacturing. Axio's focus is on the data layer that enables better decision-making and tech transfer, rather than direct manufacturing at scale.

The rise of virtual biotechs and academic spin-outs, which lack internal production capabilities, requires partners to manage data for pre-clinical and early-phase clinical trials [McKinsey & Company, 2023]. Axio's positioning addresses a critical pain point in this segment, where speed to proof-of-concept data directly impacts fundraising and valuation.

Regulatory and macro forces present both a hurdle and a potential moat. Biologics manufacturing is heavily regulated by agencies like the U.S. Food and Drug Administration, requiring strict adherence to Current Good Manufacturing Practice (cGMP) standards. Macroeconomic pressures, including higher cost of capital, may push biotechs to seek more cost-effective, on-demand data management partners rather than committing to large, upfront capital expenditures.

Data Accuracy: YELLOW -- Market sizing is from a third-party analyst report cited in secondary coverage; specific drivers and regulatory context are supported by general industry analysis.

Who Else Is Fighting for This

Axio BioPharma enters a biomanufacturing market defined by scale, where its data coordination approach carves out a niche focused on improving efficiency across the ecosystem. The landscape for bioprocess data platforms includes companies offering data integration, analytics, and process intelligence solutions.

Axio claims a defensible edge in providing a vendor-neutral data coordination layer that normalizes and connects process data across pharma sponsors and manufacturing partners. This edge rests on its proprietary technology, the 'Axio Lattice' for data structuring, and a partnership strategy, as seen with Likarda, to streamline the path to clinical manufacturing. The company's physical presence at Forward BioLabs in Madison provides a low-cost, flexible operational base.

Exposure for Axio is acute in several dimensions. It lacks the capital infrastructure to compete on volume or move upstream into clinical trial material production. A named competitor's specific advantage would be an incumbent like Thermo Fisher Scientific or a venture-backed startup like Benchling, which could apply automation and software to the same research-scale problem with greater brand recognition and sales reach. Furthermore, Axio does not own a proprietary cell line or expression platform. Its channel is nascent, with no publicly disclosed customer contracts, leaving it vulnerable to being circumvented by biotechs choosing to build internal capability or partner with a better-funded, full-service provider.

Data Accuracy: ORANGE -- Competitive analysis is inferred from market structure and company claims; no direct competitor data is publicly available.

Opportunity

If Axio BioPharma can successfully automate and coordinate the early-stage biologics development cycle, it could capture a meaningful share of the market for biomanufacturing data infrastructure, a segment that is foundational to the $200+ billion biopharmaceutical pipeline [BioSpace, 2026].

Axio's goal is to become the default, data-native coordination layer for preclinical and early-stage biologic programs. By embedding data coordination into process development at this specific, high-volume stage, Axio aims to build a reputation for speed and predictability that could make it the preferred first stop for emerging biotechs and large pharma research units.

Scenario	What happens	Catalyst
The Likarda Partnership Flywheel	The strategic partnership with biologic delivery technology partner Likarda becomes a blueprint.	Successful execution and public case studies from the Likarda collaboration [Pharma Manufacturing, 2026].
Data Platform Commercialization	The internally developed "Axio Lattice" data alignment platform is productized and licensed to other biopharma partners.	Completion of current feasibility and proof-of-concept engagements with external partners.
Regional Cluster Dominance	Axio becomes the central, go-to manufacturing hub for the growing Madison and Midwest biotech cluster.	Securing a lead anchor tenant customer from the local ecosystem.

Data Accuracy: YELLOW -- Opportunity framing relies on company claims and announced partnerships; market size context is from secondary industry reporting.

Sources

[Pharma Manufacturing, 2026] Axio Biopharma, Likarda partner to streamline biologic drug development | https://www.pharmamanufacturing.com/industry-news/news/55296353/axio-biopharma-likarda-partner-to-streamline-biologic-drug-development
[BioSpace, 2026] Axio BioPharma and Likarda Announce Strategic Partnership to Accelerate Biologic Drug Development and Delivery | https://www.biospace.com/press-releases/axio-biopharma-and-likarda-announce-strategic-partnership-to-accelerate-biologic-drug-development-and-delivery
[WEDC, 2024] Axio BioPharma Inc. | https://wedc.org/innovate-in-wisconsin/innovation-investment-portfolio/axio-biopharma-inc/
[InBusiness Madison, Sept 2025] InBusiness: Moving from the Lab to the Medicine Cabinet | https://www.axiobiopharma.com/news/in-business-moving-from-the-lab-to-the-medicine-cabinet
[Axio BioPharma, June 2025] News & Insights | https://www.axiobiopharma.com/news
[Axio BioPharma, Unknown] Axio BioPharma: One Year In | https://www.axiobiopharma.com/news/axio-biopharma-one-year-in
[Axio BioPharma, Unknown] Axio BioPharma | https://www.axiobiopharma.com
[PRNewswire, Sept 2024] Axio BioPharma Launches Protein Manufacturing Services | https://www.prnewswire.com/news-releases/axio-biopharma-lunches-protein-manufacturing-services-302253594.html
[LinkedIn, 2026] Patrick Haffey - Healthcare | Technology | Manufacturing | LinkedIn | https://www.linkedin.com/in/patrick-haffey-844b0845/
[IQVIA Institute, 2024] Global Trends in R&D 2024 | https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d-2024
[McKinsey & Company, 2023] Biopharma outsourcing: The next frontier | https://www.mckinsey.com/industries/life-sciences/our-insights/biopharma-outsourcing-the-next-frontier